ImmuneWalk Therapeutics raised $7M in Seed financing to expand operations and R&D efforts.

May 08, 2025•8 months ago

Amount Raised

$7 Million

Round Type

seed

Pearl RiverTherapeuticsBiotechnologyHealth Care

Investors

Immune Walk Management TeamInstitutional Investor

Description

ImmuneWalk Therapeutics, a NYC-based clinical stage company focused on modulating immune and inflammatory disease, raised $7M in Seed funding. Backers included institutional investors and the ImmuneWalk management team. The funds will be used to expand operations and R&D efforts. Their lead candidate, IW-601, is in Phase 1 clinical trial.

Company Information

Company

ImmuneWalk Therapeutics

Location

Pearl River, New York, United States

About

ImmuneWalk Therapeutics is a clinical-stage biotechnology company dedicated to developing new therapies for immune-inflammatory diseases. Central to their program is the discovery of a new adhesion checkpoint that regulates the migration of specific immune cells into inflamed tissues. Their lead candidate, IW-601, is an engineered monoclonal antibody demonstrating disease-modifying activity in preclinical models of several diseases. They are currently conducting the POINTGUARD Phase 1 clinical trial.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns